CN106977506A - 二氢黄酮衍生物、其制备方法和用途 - Google Patents
二氢黄酮衍生物、其制备方法和用途 Download PDFInfo
- Publication number
- CN106977506A CN106977506A CN201610032327.6A CN201610032327A CN106977506A CN 106977506 A CN106977506 A CN 106977506A CN 201610032327 A CN201610032327 A CN 201610032327A CN 106977506 A CN106977506 A CN 106977506A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- group
- disease
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 150000002207 flavanone derivatives Chemical class 0.000 title abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 106
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- -1 pyrrole radicals Chemical class 0.000 claims description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
- 201000010099 disease Diseases 0.000 claims description 33
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 26
- MSTDXOZUKAQDRL-UHFFFAOYSA-N 4-Chromanone Chemical compound C1=CC=C2C(=O)CCOC2=C1 MSTDXOZUKAQDRL-UHFFFAOYSA-N 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 201000000980 schizophrenia Diseases 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 15
- 229910052731 fluorine Inorganic materials 0.000 claims description 15
- 239000011737 fluorine Substances 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 12
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 208000020016 psychiatric disease Diseases 0.000 claims description 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 229940049706 benzodiazepine Drugs 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 9
- 230000002490 cerebral effect Effects 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 210000005036 nerve Anatomy 0.000 claims description 8
- 208000016192 Demyelinating disease Diseases 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 208000020431 spinal cord injury Diseases 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 4
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 claims description 4
- 238000006073 displacement reaction Methods 0.000 claims description 4
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 230000000269 nucleophilic effect Effects 0.000 claims description 4
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 3
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 claims description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 150000003214 pyranose derivatives Chemical class 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 125000005493 quinolyl group Chemical group 0.000 claims description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 229940126062 Compound A Drugs 0.000 claims description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 2
- 208000034800 Leukoencephalopathies Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 238000005575 aldol reaction Methods 0.000 claims description 2
- 125000001118 alkylidene group Chemical group 0.000 claims description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims description 2
- 238000005906 dihydroxylation reaction Methods 0.000 claims description 2
- 230000001037 epileptic effect Effects 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- 208000016686 tic disease Diseases 0.000 claims description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical class COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 30
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 28
- 229960003638 dopamine Drugs 0.000 abstract description 14
- 230000008859 change Effects 0.000 abstract description 11
- 210000001642 activated microglia Anatomy 0.000 abstract description 8
- 230000008485 antagonism Effects 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 5
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract description 3
- 230000003959 neuroinflammation Effects 0.000 abstract description 3
- 238000010171 animal model Methods 0.000 abstract description 2
- 230000001629 suppression Effects 0.000 abstract description 2
- 239000002585 base Substances 0.000 description 38
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 29
- 238000010172 mouse model Methods 0.000 description 25
- 235000002639 sodium chloride Nutrition 0.000 description 23
- DSRJIHMZAQEUJV-UHFFFAOYSA-N Cuprizon Chemical compound C1CCCCC1=NNC(=O)C(=O)NN=C1CCCCC1 DSRJIHMZAQEUJV-UHFFFAOYSA-N 0.000 description 22
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 210000000274 microglia Anatomy 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 229960001866 silicon dioxide Drugs 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 230000008925 spontaneous activity Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 239000000376 reactant Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
- 239000000164 antipsychotic agent Substances 0.000 description 7
- 229940005529 antipsychotics Drugs 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 230000008506 pathogenesis Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000003027 ear inner Anatomy 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 5
- 206010072731 White matter lesion Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000004885 white matter Anatomy 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000006386 Myelin Proteins Human genes 0.000 description 4
- 108010083674 Myelin Proteins Proteins 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000000370 acceptor Substances 0.000 description 4
- 125000005605 benzo group Chemical group 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002075 main ingredient Substances 0.000 description 4
- 210000005012 myelin Anatomy 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- AADCDMQTJNYOSS-LBPRGKRZSA-N 5-chloro-3-ethyl-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(O)C(CC)=CC(Cl)=C1OC AADCDMQTJNYOSS-LBPRGKRZSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 3
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 230000003291 dopaminomimetic effect Effects 0.000 description 3
- 150000002118 epoxides Chemical class 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 229950007535 eticlopride Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000000848 glutamatergic effect Effects 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 150000002545 isoxazoles Chemical class 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical class BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 2
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 102000014384 Type C Phospholipases Human genes 0.000 description 2
- 108010079194 Type C Phospholipases Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- CWRYPZZKDGJXCA-UHFFFAOYSA-N acenaphthene Chemical compound C1=CC(CC2)=C3C2=CC=CC3=C1 CWRYPZZKDGJXCA-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000002567 autonomic effect Effects 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229930003949 flavanone Natural products 0.000 description 2
- 235000011981 flavanones Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000006724 microglial activation Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 238000012346 open field test Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- ZTRPYTHOEREHEN-UHFFFAOYSA-N piperazine pyridine Chemical compound N1CCNCC1.N1=CC=CC=C1.N1=CC=CC=C1 ZTRPYTHOEREHEN-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004309 pyranyl group Chemical class O1C(C=CC=C1)* 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- OBSLWIKITOYASJ-AZEWMMITSA-N (2r,3s,4s,5r,6s)-6-(hydroxymethyl)-3-(methylamino)oxane-2,4,5-triol Chemical class CN[C@@H]1[C@H](O)O[C@@H](CO)[C@H](O)[C@H]1O OBSLWIKITOYASJ-AZEWMMITSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical class OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- MPKCUAWIBWMDIB-UHFFFAOYSA-N COc1ccc(C(C2)Oc3cc(OCCCCN(CC4)CCC4c4n[o]c5cc(F)ccc45)cc(O)c3C2=O)cc1 Chemical compound COc1ccc(C(C2)Oc3cc(OCCCCN(CC4)CCC4c4n[o]c5cc(F)ccc45)cc(O)c3C2=O)cc1 MPKCUAWIBWMDIB-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 101710107142 Dopamine receptor 2 Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024548 aluminum oxide Drugs 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000003181 encephalopathic effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 1
- FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及二氢黄酮衍生物、其制备方法和用途,具体涉及如式I所示化合物或其药学上可接受的盐、其药物组合物、其制备方法及其预防或治疗精神障碍和神经系统疾病的用途。本发明的化合物具有优秀的抑制小胶质细胞活化和神经炎症反应活性,并能拮抗多巴胺2型受体,改善多种精神障碍动物模型的行为学变化,而且还能有效抑制神经炎症和髓鞘脱失,可用于精神障碍和神经系统疾病的预防或治疗。
Description
技术领域
本发明涉及医药领域,具体涉及二氢黄酮类衍生物、其制备方法和用途。
背景技术
精神障碍是指大脑机能活动发生紊乱,导致认知、情感、行为和意志等精神活动不同程度障碍的总称。常见的精神障碍有精神分裂症,抑郁症,躁狂抑郁性精神障碍(双相障碍),焦虑症,恐惧症,强迫症,应激相关障碍,以及各种器质性病变伴发的精神障碍等。据统计,非感染性疾病占全球负担的比重日益增加,精神障碍占整个疾病负担的15%以上。我国精神疾病在我国疾病总负担中排名首位,约占疾病总负担的20%。据报道,我国精神疾病发病率已高达17.5%,其中重性精神障碍发病率高达1%。
在发病机制方面,单胺类递质及其受体是精神医学研究得最广泛的神经递质和受体之一。在精神分裂症的发病机制中,主要有多巴胺(DA)活动过度假说、5-羟色胺(5-HT)和去甲肾上腺素(NE)神经通路障碍假说。研究表明,精神分裂症患者的阳性症状(幻觉、妄想等)可能与皮质下边缘系统DA功能亢进有关。通过阻断多巴胺2型受体(DRD2)发挥药理作用的抗精神病药物能有效控制精神分裂症的阳性症状。
谷氨酸和天门冬氨酸是中枢神经系统最常见的兴奋性神经递质。有研究提示精神分裂症和其他精神障碍涉及谷氨酸能传递异常。N-甲基-D-天冬氨酸(N-methyl-D-aspartic acid,NMDA)受体拮抗剂能够诱导精神分裂症样效应;增强NMDA受体功能的物质能够改善精神分裂症患者的症状和认知功能。
现在越来越多的证据表明,炎症和免疫功能异常可能与精神分裂症、抑郁症和其他精神障碍的发生发展有密切关系。在精神分裂症患者和具有精神分裂高风险的患者大脑内,免疫细胞(小胶质细胞)更活跃,表明神经炎性反应是精神分裂的一个重要因素,并成为了治疗和预防精神分裂症的一个新的潜在目标。此外,针对人类的尸检研究及特殊的成像学技术,以及动物抑郁模型研究显示,当小胶质细胞发生改变,无法继续调节脑内功能及行为进程时,即可发生抑郁。长期暴露于慢性的、无法预测的心理应激也可导致小胶质细胞的形状及功能发生改变,而这种应激同样也是导致人类抑郁的最首要原因之一。
已有大量研究表明,小胶质细胞激活和神经炎症是神经退行性疾病(如阿尔茨海默病、帕金森病)、脑血管病、脑创伤、脊髓损伤、脱髓鞘病、多发性硬化、脑脊髓炎等神经系统疾病的重要发病机制。
神经白质是中枢神经系统的重要组成部分,是神经纤维聚集的地方,中枢神经细胞的髓鞘损害,会引起白质病变。精神分裂症、抑郁症和其他精神障碍患者,以及脑血管病、糖尿病性神经病等出现白质神经纤维的异常,如髓鞘的变化、轴突的紊乱等,而且多发性硬化等脱髓鞘疾病可出现精神障碍症状。这些结果表明神经白质病变与精神障碍和一些神经系统疾病的发病机制密切相关。
目前,临床上应用的抗精神病药物可分为两类:一类是具有阻断多巴胺受体作用的第一代抗精神病药物,称为“经典”抗精神病药物(如氟哌啶醇等),它们虽然能有效控制精神分裂症的阳性症状,但对认知障碍的疗效甚差;另一类是与多巴胺受体和其他受体(如5-羟色胺受体、去甲肾上腺素受体)共同作用的药物,称为“非经典”抗精神病药物(如齐拉西酮、利培酮等),该类药物虽然对精神分裂症的阳性症状和阴性症状有一定疗效,但同样地,其对认知障碍的疗效较差。
综上所述,当前仍缺乏能够改善认知障碍的抗精神病药物,另外,对于能够同时作用在多巴胺能系统、谷氨酸能系统、小胶质细胞、脑白质等精神障碍和神经疾病复杂发病机制多靶点的药物的研究不足。
因此,研制作用在多靶点的抗精神障碍和神经疾病药物对临床治疗具有重要意义。
发明内容
本发明的发明人通过对二氢黄酮类化合物进行结构修饰得到一类结构新颖的化合物,其能够同时作用在多巴胺能系统、谷氨酸能系统、小胶质细胞、脑白质等多靶点,可用于预防或治疗精神障碍或神经系统疾病,本发明即是基于以上发现而完成。
基于以上发现,本发明的目的在于以下的任一项:1.提供一类结构新颖的二氢黄酮衍生物或其药学上可接受的盐,其制备方法,以及包含所述衍生物或其药学上可接受的盐的药物组合物;2.提供所述二氢黄酮衍生物或其药学上可接受的盐、药物组合物在制备用于预防或治疗精神障碍或神经系统疾病的药物中的用途;3.提供一种预防或治疗精神障碍或神经系统疾病的方法,其包括向有此需要的患者给予所述二氢黄酮衍生物或其药学上可接受的盐、药物组合物;4.所述二氢黄酮衍生物或其药学上可接受的盐、药物组合物,其用于预防或治疗精神障碍和神经系统疾病。
更具体地说,本发明第一方面提供式(I)所示化合物或其药学上可接受的盐,
R1、R2、R3、R4、R5、R6、R7和R8各自独立地选自氢、卤素、氰基、羟基、氨基、C1-6烷基(例如甲基)、C1-6烷氧基(例如甲氧基)、C1-6烷氨基和芳基,任选地,其中所述C1-6烷基、C1-6烷氧基、C1-6烷氨基和芳基各自独立地被一个或多个选自卤素、氨基和羟基的取代基取代,优选地,其中所述卤素为氯或氟;
X为含有2-6个碳原子的饱和或部分饱和的亚链烃基,任选地,其中所述亚链烃基被选自羟基或甲基的取代基取代;
Y为-N-或-C(R)-,其中所述R基选自氢、羟基、氨基、C1-6烷基;
Z为芳基或杂芳基。
在本发明的一个实施方案中,R3和R8各自独立地选自氢、卤素(例如氟或氯)、C1-6烷基(例如甲基)和C1-6烷氧基(例如甲氧基),任选地,其中所述C1-6烷基和C1-6烷氧基各自独立地被一个或多个选自卤素、氨基和羟基的取代基取代;
其余各原子或取代基如本发明第一方面任一项所述。
在本发明的一个实施方案中,R1、R2、R4、R5、R6和R7均为氢;
其余各原子或取代基如本发明第一方面任一项所述。
在本发明的一个实施方案中,X为C2-6亚烷基(例如C2-4亚烷基,再例如1,2-亚乙基、1,3-亚丙基或1,4-亚丁基),任选地,所述C2-6亚烷基被选自羟基或甲基的取代基取代;
其余各原子或取代基如本发明第一方面任一项所述。
在本发明的一个实施方案中,Y为-N-或-C(R)-,其中R选自氢、羟基或甲基;
其余各原子或取代基如本发明第一方面任一项所述。
在本发明的一个实施方案中,Z为含5-20个碳原子(例如5-15个碳原子,再例如5-10个碳原子)的芳基或杂芳基,优选地,所述芳基或杂芳基选自苯基、萘基、吡咯基、呋喃基、噻吩基、咪唑基、吡唑基、噁唑基、异噁唑基、噻唑基、异噻唑基、三氮唑基、吡啶基、吡喃基、嘧啶基、吡嗪基、哒嗪基、三嗪基、吲哚基、苯并呋喃基、苯并噻吩基、苯并咪唑基、苯并吡唑基、苯并噁唑基、苯并异噁唑基、苯并噻唑基、苯并异噻唑基、苯并三氮唑基、喹啉基、苯并吡喃基、苯并嘧啶基、喹喔啉基、苯并哒嗪基、苯并三嗪基和嘌呤基;
其余各原子或取代基如本发明第一方面任一项所述。
在本发明的一个实施方案中,其中所述化合物选自:
5-羟基-2-(4-甲氧基苯基)-7-(4-(4-(2-甲氧基苯基)哌嗪-1-基)丁氧基)苯并二氢吡喃-4-酮;
5-羟基-2-(4-甲基苯基)-7-(4-(4-(2-甲氧基苯基)哌嗪-1-基)丁氧基)苯并二氢吡喃-4-酮;
5-羟基-2-(4-氟基苯基)-7-(4-(4-(2-甲氧基苯基)哌嗪-1-基)丁氧基)苯并二氢吡喃-4-酮;
5-羟基-2-(4-甲氧基苯基)-7-(4-(4-(2-甲氧基苯基)哌嗪-1-基)丙氧基)苯并二氢吡喃-4-酮;
5-羟基-2-(4-甲氧基苯基)-7-(4-(4-(6-氟-苯并[d]异噁唑-3-基)哌啶-1-基)丁氧基)苯并二氢吡喃-4-酮;
5-羟基-2-(4-甲氧基苯基)-7-(4-(4-(6-氟-苯并[d]异噁唑-3-基)哌啶-1-基)丙氧基)苯并二氢吡喃-4-酮;和
5-羟基-2-(4-氟基苯基)-7-(4-(4-(6-氟-苯并[d]异噁唑-3-基)哌啶-1-基)丁氧基)苯并二氢吡喃-4-酮。
本发明第二方面提供了本发明第一方面任一项所述的化合物或其药学上可接受的盐的制备方法,其特征在于,先合成X基团右侧的二氢黄酮部分,然后通过一个含有2-6个碳原子的碳链与取代苯基或1,2-苯并异噁唑基取代的哌嗪基或哌啶基连接而成,其中各基团或符号定义如本发明第一方面任一项所述。
在本发明的一个实施方案中,所述方法包括以下步骤:
1)化合物A与乙酰氯经酰基化反应得到化合物B;
2)在化合物B的羟基上引入保护基得化合物C;
3)化合物C与化合物D发生羟醛缩合反应制得化合物E;
4)化合物E经关环反应得化合物F;
5)化合物F脱羟基保护基得化合物G;
6)化合物G与化合物H经亲核取代得到化合物I;
7)化合物I与化合物J经亲核取代得到式I化合物;
其中,PG代表羟基保护基,例如MOM、TMS或TBS等;L表示亲核取代反应的离去基团,例如卤素、-OTs、-OCOR(R代表烷基)等;
其余各原子或取代基定义如本发明第一方面任一项所述。
本发明的第三方面提供了一种药物组合物,其包含本发明第一方面任一项所述的式I化合物或其药学上可接受的盐,以及任选地一种或多种药学上可接受的辅料(如载体和/或赋形剂等)。
本发明还提供了本发明第一方面任一项所述的式I化合物或其药学上可接受的盐、或本发明第三方面所述的药物组合物在制备用于治疗或预防精神障碍或神经系统疾病的药物中的用途。
本发明还提供了一种预防或治疗精神障碍或神经系统疾病的方法,其包括向有此需要的受试者给予有效量的本发明第一方面任一项所述的式I化合物或其药学上可接受的盐、或本发明第三方面任一项所述的药物组合物。
本发明还提供本发明第一方面任一项所述的式I化合物或其药学上可接受的盐、或本发明第三方面任一项所述的药物组合物,其用于预防或治疗精神障碍或神经系统疾病。
本发明所述的精神障碍选自精神分裂症、抑郁症、躁狂抑郁性精神障碍(双相障碍)、认知障碍、焦虑症、应激相关障碍、注意缺陷与多动障碍、抽动障碍,以及各种器质性病变伴发的精神障碍等。
在本发明的一个实施方案中,所述各种器质性病变伴发的精神障碍选自阿尔茨海默病、血管性痴呆、脑外伤所致精神障碍、颅内感染所致精神障碍、脑肿瘤所致精神障碍、梅毒所致精神障碍、癫痫性精神障碍和HIV/AIDS所致精神障碍。
本发明所述的神经系统疾病选自神经退行性疾病(阿尔茨海默病、帕金森病)、脑血管病、脑创伤、脊髓损伤、脱髓鞘病、多发性硬化、炎症性脱髓鞘性多发性神经病、缺血-缺氧性病引起的白质脑病和糖尿病性神经病。
以下对本发明的术语进行解释,对于特定的术语,如果本发明中的含义与本领域技术人员通常理解的含义不一致,以本发明中的含义为准;如果在本发明中没有定义,则其具有本领域技术人员通常理解的含义。除非有相反陈述,本发明中使用的术语具有下述含义:
本发明所用术语“C1-6烷基”是指具有1-6个碳原子的直链或支链烷基,例如C1烷基、C2烷基、C3烷基、C4烷基、C5烷基或C6烷基。具体的实例包括但不限于甲基、乙基、丙基、异丙基、丁基、叔丁基、戊基、己基等。
本发明中所用术语“C1-6烷氧基”是指具有“C1-6烷基-O-”结构的基团,其中C1-6烷基具有前述相同的含义。例如C1烷氧基、C2烷氧基、C3烷氧基、C4烷氧基、C5烷氧基或C6烷氧基。具体的实例包括但不限于甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、叔丁氧基、戊氧基、己氧基等。
本发明中所用术语“C1-6烷氨基”是指具有“C1-6烷基-NH-”结构的基团,其中C1-6烷基具有前述相同的含义。例如C1烷氨基、C2烷氨基、C3烷氨基、C4烷氨基、C5烷氨基或C6烷氨基。具体的实例包括但不限于甲氨基、乙氨基、丙氨基、异丙氨基、丁氨基、叔丁氨基、戊氨基、己氨基等。
本发明中所用术语“芳基”是指具有单环(如苯基)、多环(如萘基)或其中至少一个环是芳香性的稠合环(如1,2,3,4-四氢萘基)的芳族碳环基。例如含有5-20个(例如5-15个或5-10个)碳原子的芳基。具体的实例包括但不限于苯基、萘基、蒽基、菲基、芴基、茚基、苊基等。
本发明中所用术语“杂芳基”是指含有至少一个至多四个选自N、O或S的杂原子的具有芳香性的环状基团,例如含有5-20个(例如5-15个或5-10个)碳原子的杂芳基。具体的实例包括但不限于、吡咯基、呋喃基、噻吩基、咪唑基、吡唑基、噁唑基、异噁唑基、噻唑基、异噻唑基、三氮唑基、吡啶基、吡喃基、嘧啶基、吡嗪基、哒嗪基、三嗪基、吲哚基、苯并呋喃基、苯并噻吩基、苯并咪唑基、苯并吡唑基、苯并噁唑基、苯并异噁唑基、苯并噻唑基、苯并异噻唑基、苯并三氮唑基、喹啉基、苯并吡喃基、苯并嘧啶基、喹喔啉基、苯并哒嗪基、苯并三嗪基和嘌呤基等。
本发明中所用术语“饱和的或部分饱和的亚链烃基”是指饱和的或部分饱和的链烃基上失去两个氢原子后剩余的部分,例如含有2-6个碳原子的饱和的或部分饱和的亚链烃基,例如含有2-6个碳原子的亚烷基。具体的实例包括但不限于亚甲基、亚乙基、亚丙基、亚丁基、1,2-亚乙基、1,3-亚丙基、1,4-亚丁基、1,5-亚戊基、1,6-亚己基等。
本发明所用术语“卤素”包括氟、氯、溴和碘。
本发明的化合物可以含有手性中心,且可以以不同的对映体和非对映体形式存在。本发明化合物的所有旋光异构体,或外消旋混合物均在本发明的保护范围之内。
本发明中所用术语“药学上可接受的”通常是指制药学上或医学上可用的,或者虽然不能直接用于制药学或医学,但是可作为制备制药学或医学产品中间体时可以利用,并在最后用于制药学或医学之前通过适宜的方法脱除的。例如药学上可接受的盐,不但包括可用于临床的药用盐,还包括不能直接用于临床,但可在制备本发明化合物时使用并在随后的工艺过程中脱除的盐。本发明中所用术语“药学上可接受的盐”包括与药学上可接受的无机酸或有机酸或者无机碱或有机碱形成的常规的盐以及季铵与酸形成的盐。合适的酸盐的例子包括但不限于盐酸盐、氢溴酸盐、硫酸盐、磷酸盐、硝酸盐、高氯酸盐、富马酸盐、乙酸盐、丙酸盐、丙酮酸盐、琥珀酸盐、羟基乙酸盐、甲酸盐、乳酸盐、马来酸盐、酒石酸盐、柠檬酸盐、扑酸盐、丙二酸盐、戊二酸盐、羟基马来酸盐、苯乙酸盐、谷氨酸盐、苯甲酸盐、水杨酸盐、富马酸盐、甲苯磺酸盐、甲磺酸盐、萘-2-磺酸盐、苯磺酸盐、羟基萘甲酸盐、氢碘酸盐、苹果酸盐、硬脂酸盐、鞣酸盐等。其它的如草酸盐,虽然其本身并非药学上可接受的,但可以用于制备用作中间体的盐,以获得本发明化合物及其药学上可接受的盐。合适的碱盐的更具体的例子包括钠盐、锂盐、钾盐、镁盐、铝盐、钙盐、锌盐、铵盐、三乙胺盐、叔丁胺盐、N,N'-二苄基乙二胺盐、普鲁卡因盐、氯代普鲁卡因盐、胆碱盐、二乙醇胺盐、乙二胺盐和N-甲基葡糖胺盐等。
本发明中所用术语“辅料”是指除药物活性成分以外,在安全性方面已经进行了合理的评估,且包含在药物制剂中的物质。例如载体或赋形剂,这里的载体包括但不限于:离子交换剂,氧化铝,硬脂酸铝,卵磷脂,血清蛋白如人血白蛋白,缓冲物质如磷酸盐,甘油,山梨酸,山梨酸钾,饱和植物脂肪酸的部分甘油酯混合物,水,盐或电解质,如硫酸鱼精蛋白,磷酸氢二钠,磷酸氢钾,氯化钠,锌盐,胶态氧化硅,三硅酸镁,聚乙烯吡咯烷酮,纤维素物质,聚乙二醇,羧甲基纤维素钠,聚丙烯酸酯,蜂蜡,羊毛脂;所述赋形剂是指在药物制剂中除主药以外的附加物,其性质稳定,与主药无配伍禁忌,不产生副作用,不影响疗效,在常温下不易变形、干裂、霉变、虫蛀、对人体无害、无生理作用,不与主药产生化学或物理作用,不影响主药的含量测定等。如片剂中的黏合剂、填充剂、崩解剂、润滑剂;中药丸剂中的酒、醋、药汁等;半固体制剂软膏剂、霜剂中的基质部分;液体制剂中的防腐剂、抗氧剂、矫味剂、芳香剂、助溶剂、乳化剂、增溶剂、渗透压调节剂、着色剂等均可称为赋形剂,等等。
在本发明的实施方案中,所述受试者为哺乳动物,例如牛科动物、马科动物、羊科动物、猪科动物、犬科动物、猫科动物、啮齿类动物、灵长类动物;其中,特别优选的受试者为人。
本发明的化合物或药物组合物适用于口服、胃肠外(静脉内、肌肉或皮下),经皮、经舌或呼吸给药等给药途径。其中优选口服、胃肠外(静脉内、肌肉或皮下)的给药方式。
当口服用药时,本发明的化合物可制成任意口服可接受的制剂形式,包括但不限于片剂、丸剂、散剂、糖浆剂、胶囊、水溶液或水悬浮液等。其中,片剂使用的载体一般包括乳糖和玉米淀粉,另外也可加入润滑剂如硬脂酸镁。胶囊制剂使用的稀释剂一般包括乳糖和干燥玉米淀粉。水悬浮液制剂则通常是将活性成分与适宜的乳化剂和悬浮剂混合使用。如果需要,以上口服制剂形式中还可加入一些甜味剂、芳香剂或着色剂。
本发明的化合物还可以无菌注射制剂形式用药,包括无菌注射水或油悬浮液或无菌注射溶液。其中,可使用的载体和溶剂包括水、林格氏溶液和等渗氯化钠溶液。另外,灭菌的非挥发油也可用作溶剂或悬浮介质,如单甘油酯或二甘油酯。
另外需要指出,本发明化合物的使用剂量和使用方法取决于诸多因素,包括患者的年龄、体重、性别、自然健康状况、营养状况、化合物的活性强度、服用时间、代谢速率、病症的严重程度以及诊治医师的主观判断。优选的使用剂量介于0.001至100mg/kg体重/天,更优选剂量为0.01mg/kg至50mg/kg体重/天,再更优选剂量为0.1mg/kg至25mg/kg体重/天,最优剂量为1mg/kg至10mg/kg体重/天。如果需要,有效的日剂量可出于给药目的分成多剂量;因此,单剂量组合物可含有这种数量或其分剂量,以构成日剂量。上述式I化合物的给药频率可以根据临床医生的经验和诸如患者年龄、体重、性别、一般健康状况以及疾病的类型和严重性等因素来确定,例如每天给予1次、2次、3次、4次、5次等,或者每2天一次、每3天1次、每1周1次、每2周1次等。
发明的有益效果
本发明通过对二氢黄酮类化合物进行结构修饰得到一类结构新颖的化合物,其能同时作用在多巴胺能系统、谷氨酸能系统、小胶质细胞和脑白质等多靶点上。在本发明的实施方案中,所述化合物具有优秀的抑制小胶质细胞活化和神经炎症反应活性,并能拮抗多巴胺2型受体,改善多种精神障碍动物模型的行为学变化,而且还能有效抑制神经炎症和髓鞘脱失,表明本发明的化合物具有防治精神障碍和神经系统疾病的作用,为相关疾病的治疗提供了一种新的思路。
附图说明
图1为在本发明的一个实施方案中,本发明化合物抑制LPS+INF-γ致小胶质细胞(BV2细胞)活化及一氧化氮(NO)过度产生和释放结果,其中每个样品每个浓度平行6孔,实验重复2次,数据以Mean±SE表示;##P<0.01,模型组与对照组相比;*P<0.05,**P<0.01,给药组与模型组相比;
图2为在本发明的一个实施方案中,本发明化合物对多巴胺受体2(DRD2)的拮抗活性;
图3为在本发明的一个实施方案中,本发明化合物对MK-801致精神分裂症高活动模型小鼠270分钟内自主活动影响的曲线图,小鼠放入旷场行为红外监视系统仪器中开始测试60分钟,然后空白组腹腔注射生理盐水,模型组、药物组腹腔注射MK-801,继续测定各组小鼠210分钟内的自发活动性和中央区活动情况,每10分钟检测一次,每组n=10;
图4为在本发明的一个实施方案中,本发明化合物对MK-801致精神分裂症高活动模型小鼠210分钟内自发活动总路程的影响;数据以Mean±SE表示,每组n=10;##P<0.01,模型组与对照组相比;*P<0.05给药组与模型组相比;
图5为在本发明的一个实施方案中,本发明化合物对MK-801致精神分裂症高活动模型小鼠210分钟内中央区活动距离的影响,数据以Mean±SE表示,每组n=10;##P<0.01,模型组与对照组相比;
图6为在本发明的一个实施方案中,本发明化合物对Cuprizone模型小鼠8分钟内Y-迷宫进臂次数的影响,数据以Mean±SE表示,每组n=8,*P<0.05;**P<0.01;给药与模型组相比;
图7为在本发明的一个实施方案中,本发明化合物对Cuprizone模型小鼠8分钟内Y-迷宫自发性交替反应的影响,数据以Mean±SE表示,每组n=8,#P<0.05,模型组与对照组相比;*P<0.05,给药组与模型组相比;
图8为在本发明的一个实施方案中,本发明化合物对Cuprizone模型小鼠10分钟内旷场自发活动总路程的影响,数据以Mean±SE表示,每组n=8,##P<0.01,模型组与对照组相比;*P<0.05,给药组与模型组相比;
图9为在本发明的一个实施方案中,本发明化合物对Cuprizone模型小鼠额叶皮质髓鞘碱性蛋白(myelin basic protein,MBP)的影响,其中(A)为MBP蛋白的Western blot代表性图片,小:小剂量组,25mg/kg;大:大剂量组,50mg/kg;(B)为MBP蛋白定量统计结果,数据以Mean±SE表示,n=4,##P<0.01,与对照组相比;**P<0.01,与模型组相比;
图10为在本发明的一个实施方案中,本发明化合物对Cuprizone模型小鼠脑内小胶质细胞的影响(免疫组织化学染色),数据以Means±SE表示,n=3,##P<0.01,与正常对照组相比;*P<0.05,与模型组相比。
具体实施方式
下面将结合实施例对本发明的实施方案进行详细描述,但是本领域技术人员将会理解,下列实施例仅用于说明本发明,而不应视为限定本发明的范围。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得或按照公知教导制备得到的常规产品。
实施例中所述化合物的结构是按照常规的光谱技术(红外、紫外、核磁共振或ESI-MS质谱)测定的。
A本发明化合物的合成
实施例1:5-羟基-2-(4-甲氧基苯基)-7-(4-(4-(2-甲氧基苯基)哌嗪-1-基)丁氧基)苯并二氢吡喃-4-酮(P1)的合成
1)取间苯三酚5.0g(40mmol),溶于50ml二硫化碳和15ml硝基苯的溶液中,加入15.6g(120mmol)无水三氯化铝,室温搅拌10分钟,向反应液中滴加10ml乙酰氯4.23ml(60mmol)的二硫化碳溶液,之后于50℃下加热回流1小时结束反应。减压蒸去二硫化碳,向残留物中加入10ml盐酸和50ml冰水混合物,乙酸乙酯萃取3次(50ml×3),有机层饱和氯化钠洗涤,无水硫酸钠干燥,减压蒸干乙酸乙酯,硅胶拌样,硅胶柱分离。石油醚:乙酸乙酯(2:1)洗脱,得淡黄色固体5.71g,收率85.7%。
2)取第一步产物5.0g,溶于50ml丙酮中,加入无水碳酸钾15g,在室温下缓慢滴加氯甲基甲醚1.58ml,20min滴完,之后于室温下继续搅拌2小时,反应结束。滤掉无水碳酸钾固体,减压蒸去丙酮溶液,残余物中加入20ml水,乙酸乙酯萃取3次(30ml×3),有机层用饱和氯化钠洗涤,无水硫酸钠干燥,减压蒸干有机溶剂,硅胶拌样,硅胶柱分离。石油醚:乙酸乙酯(15:1)洗脱,得淡黄色油状物约4.3g,收率56.4%。
3)取第二步产物4g,氢氧化钠10g,甲醇100ml,对甲氧基苯甲醛3.64ml,加热回流5小时,冷至室温,减压蒸干溶剂,加入50ml蒸馏水,2%HCl溶液中和至中性,乙酸乙酯萃取3次(50ml×3),有机层用饱和氯化钠洗涤,无水硫酸钠干燥,减压蒸干乙酸乙酯,硅胶拌样,硅胶柱分离。先用石油醚洗脱5个柱体积,再用石油醚:乙酸乙酯(10:1)洗脱,得黄色固体4.98g,收率85.2%。
1H NMR(300MHz,DMSO-d6):δ=12.39(br s,1H,OH-5),7.67(d,2H,J=8.7Hz,Ar-H),7.53(d,2H,J=9.6Hz,Ar-H),7.01(d,2H,J=9.0Hz,Ar-H),5.28(s,2H,-OCH2-),5.22(s,2H,-OCH2-),3.81(s,3H,-OCH3),3.40(s,3H,-OCH3),3.40(s,3H,-OCH3).
4)取第三步产物2g,乙酸钠8g,甲醇30ml,加热回流12小时,冷至室温,减压蒸干溶剂,加入30ml蒸馏水,乙酸乙酯萃取3次(20ml×3),有机层用饱和氯化钠洗涤,无水硫酸钠干燥,减压蒸干乙酸乙酯,硅胶拌样,硅胶柱分离。先用石油醚:乙酸乙酯(10:1)洗脱4个柱体积,再用石油醚:乙酸乙酯(3:1)洗脱,得无色油状物1.63g,收率81.5%。
1H NMR(300MHz,DMSO-d6):δ=7.44(d,2H,J=8.7Hz,Ar-H),6.97(d,2H,J=8.7Hz,Ar-H),6.36(d,1H,J=2.1Hz,H-8),6.33(d,1H,J=2.4Hz,H-6),5.50(dd,1H,J=12.9,2.7Hz,H-2),5.23(s,2H,-OCH2-),5.22(s,2H,-OCH2-),3.77(s,3H,-OCH3),3.41(s,3H,-OCH3),3.38(s,3H,-OCH3),3.14(dd,1H,J=16.2,12.9Hz,H-3α),2.60(dd,1H,J=16.2,2.7Hz,H-3β).
5)取第四步产物1.5g,甲醇30ml,浓盐酸1ml,加热回流30分钟,冷至室温,减压蒸干溶剂,少量甲醇混悬,倒入100ml冰水混合物中,减压抽滤,滤饼烘干后得白色固体0.87g,收率72.3%。
1H NMR(300MHz,DMSO-d6):δ=12.14(br s,1H,OH-5),10.78(br s,1H,OH-7),7.44(d,2H,J=8.7Hz,Ar-H),6.97(d,2H,J=8.7Hz,Ar-H),5.90(br s,1H,H-8),5.89(br s,1H,H-6),5.50(dd,1H,J=12.6,2.7Hz,H-2),3.77(s,3H,-OCH3),3.28(dd,1H,J=14.1,12.6Hz,H-3α),2.72(dd,1H,J=14.1,3.0Hz,H-3β).
6)取第五步产物0.8g,无水碳酸钾3g,丙酮20ml,1,4-二溴丁烷1.2g,加热回流3小时,冷至室温,滤掉无水碳酸钾固体,有机层硅胶拌样,硅胶柱分离,石油醚:乙酸乙酯(15:1)洗脱,得黄色油状物0.61g,收率54.5%。
ESI+-MS:423.1[M+H]+
1H NMR(300MHz,CDCl3):δ=12.03(br s,1H,OH-5),7.40(d,2H,J=8.7Hz,Ar-H),6.97(d,2H,J=8.7Hz,Ar-H),6.06(d,1H,J=2.4Hz,H-8),6.04(d,1H,J=2.4Hz,H-6),5.38(dd,1H,J=12.9,3.0Hz,H-2),4.04(t,2H,J=6.0Hz,H-1”),3.85(s,3H,-OCH3),3.49(t,2H,J=6.0Hz,H-4”),3.11(dd,J=17.1,12.9Hz,H-3α),2.80(dd,1H,J=17.1,3.0Hz,H-3β),2.68(m,4H,H2-2”’;H2-6”’),2.49(t,2H,J=7.2Hz,H-5”’),2.09(m,2H,H-3”),1.96(m,2H,H-2”).
7)取第六步产物0.6g,无水碳酸钾2g,碘化钾0.5g,乙腈10ml,1-(2-甲氧基苯基)哌嗪0.68g,加热回流2小时,冷至室温,滤掉无水碳酸钾固体,有机层硅胶拌样,硅胶柱分离,石油醚:乙酸乙酯(2:1)洗脱,得黄色油状物0.15g,收率19.7%。
ESI+-MS:532.9[M+H]+
HR-Q-TOF-MS:533.2712[M+H]+(calcd for C31H36N2O6,533.2646).
1H NMR(300MHz,CDCl3):δ=12.04(br s,1H,OH-5),7.40(d,2H,J=8.7Hz,Ar-H),6.90(m,6H,Ar-H),6.08(d,1H,J=2.1Hz,H-8),6.05(br s,1H,J=1.8Hz,H-6),5.38(dd,1H,J=12.9,2.7Hz,H-2),4.03(t,2H,J=6.0Hz,H-1”),3.88(s,3H,-OCH3),3.85(s,3H,-OCH3),3.11(m,5H,H2-4”;H2-3”’;H-3α),2.80(dd,1H,J=17.1,3.0Hz,H-3β),2.68(m,4H,H2-2”’;H2-6”’),2.49(t,2H,J=7.2Hz,H-5”’),1.85(m,2H,H-2”),1.70(m,2H,H-3”).13CNMR(300MHz,CDCl3):δ=195.9(C-4),167.5(C-7),164.1(C-7”’),162.9(C-5),160.1(C-4’),152.3(C-9),141.4(C-8”’),130.5(C-1’),127.7(C-2’,6’),122.9(C-12”’),121.0(C-10”’),118.2(C-11”’),114.2(C-3’,5’),111.3(C-9”’),103.1(C-10),95.6(C-6),94.6(C-8),79.0(C-2),68.3(C-1”),58.1(C-4”),55.4(2×-OCH3),53.4(C-3”’,5”’),50.6(C-2”’,6”’),43.2(C-3),27.0(C-2”),23.2(C-3”).
实施例2:5-羟基-2-(4-甲基苯基)-7-(4-(4-(2-甲氧基苯基)哌嗪-1-基)丁氧基)苯并二氢吡喃-4-酮(P2)的合成
操作同实施例1,在步骤3)中使用对甲基苯甲醛作为反应物。
ESI+-MS:517.2[M+H]+
HR-Q-TOF-MS:517.2766[M+H]+(calcd for C31H36N2O5,517.2697).
1H NMR(300MHz,CDCl3):δ=12.03(br s,1H,OH-5),7.36(d,2H,J=8.1Hz,Ar-H),7.26(d,2H,J=7.8Hz,Ar-H),6.95(m,4H,Ar-H),6.08(d,1H,J=2.7Hz,H-8),6.06(br s,1H,J=2.4Hz,H-6),5.40(dd,1H,J=12.9,3.0Hz,H-2),4.03(t,2H,J=6.3Hz,H-1”),3.88(s,3H,-OCH3),3.10(m,5H,H2-4”;H2-3”’;H-3α),2.82(dd,1H,J=17.1,3.0Hz,H-3β),2.69(m,4H,H2-2”’;H2-6”’),2.49(t,2H,J=7.2Hz,H-5”’),2.40(s,3H,-CH3),1.83(m,2H,H-2”),1.71(m,2H,H-3”).13C NMR(300MHz,CDCl3):δ=195.8(C-4),167.5(C-7),164.1(C-7”’),162.9(C-5),152.3(C-9),141.4(C-8”’),138.8(C-4’),135.5(C-1’),129.5(C-2’,6’),126.2(C-3’,5’),122.9(C-12”’),121.0(C-10”’),118.2(C-11”’),111.3(C-9”’),103.1(C-10),95.6(C-6),94.6(C-8),79.1(C-2),68.3(C-1”),58.1(C-4”),55.4(2-OCH3),53.4(C-3”’,5”’),50.6(C-2”’,6”’),43.3(C-3),27.0(C-2”),23.2(C-3”),21.2(-CH3).
实施例3:5-羟基-2-(4-氟基苯基)-7-(4-(4-(2-甲氧基苯基)哌嗪-1-基)丁氧基)苯并二氢吡喃-4-酮(P3)的合成
操作同实施例1,在步骤3)中使用对氟苯甲醛作为反应物,所得产物P3为黄色油状物。
ESI+-MS:520.8[M+H]+
HR-Q-TOF-MS:521.2506[M+H]+(calcd for C30H33FN2O5,521.2446).
1H NMR(300MHz,CDCl3):δ=12.01(br s,1H,OH-5),7.45(m,2H,Ar-H),7.16(m,2H,J=7.8Hz,Ar-H),6.95(m,4H,Ar-H),6.10(d,1H,J=2.4Hz,H-8),6.06(d,1H,J=2.1Hz,H-6),5.40(dd,1H,J=13.2,3.0Hz,H-2),4.03(t,2H,J=6.0Hz,H-1”),3.88(s,3H,-OCH3),3.06(m,5H,H2-4”;H2-3”’;H-3α),2.82(dd,1H,J=17.1,3.3Hz,H-3β),2.68(m,4H,H2-2”’;H2-6”’),2.49(t,2H,J=7.5Hz,H-5”’),2.40(s,3H,-CH3),1.82(m,2H,H-2”),1.70(m,2H,H-3”).13C NMR(300MHz,CDCl3):δ=195.3(C-4),167.6(C-7),164.2(C-7”’),162.6(C-5),152.3(C-9),141.4(C-8”’),134.4(C-4’),134.3(C-1’),128.0(C-2’,6’),122.9(C-12”’),121.0(C-10”’),118.2(C-11”’),116.0(C-3’),115.7(C-3’),111.3(C-9”’),103.0(C-10),95.7(C-6),94.7(C-8),78.5(C-2),68.3(C-1”),58.1(C-4”),55.4(2-OCH3),53.5(C-3”’,5”’),50.6(C-2”’,6”’),43.4(C-3),27.0(C-2”),23.2(C-3”).
实施例4:5-羟基-2-(4-甲氧基苯基)-7-(4-(4-(2-甲氧基苯基)哌嗪-1-基)丙氧基)苯并二氢吡喃-4-酮(P6)的合成
操作同实施例1,在步骤6)中使用1,3-二溴丙烷作为反应物,所得产物P3为黄色油状物。
ESI+-MS:519.0[M+H]+
HR-Q-TOF-MS:519.2548[M+H]+(calcd for C30H34N2O6,519.2490).
1H NMR(300MHz,CDCl3):δ=12.04(br s,1H,OH-5),7.40(d,2H,J=8.4Hz,Ar-H),6.96(m,6H,Ar-H),6.09(br s,1H,H-8),6.08(br s,1H,H-6),5.38(dd,1H,J=12.9,2.4Hz,H-2),4.08(t,2H,J=6.0Hz,H-1”),3.88(s,3H,-OCH3),3.85(s,3H,-OCH3),3.11(m,5H,H2-3”;H2-3”’;H-3α),2.80(dd,1H,J=17.1,3.0Hz,H-3β),2.69(m,4H,H2-2”’;H2-6”’),2.58(t,2H,J=7.2Hz,H-5”’),2.03(m,2H,H-2”).13C NMR(300MHz,CDCl3):δ=196.0(C-4),167.2(C-7),164.1(C-7”’),162.9(C-5),160.1(C-4’),152.2(C-9),140.8(C-8”’),130.4(C-1’),127.7(C-2’,6’),123.3(C-12”’),121.1(C-10”’),118.4(C-11”’),114.2(C-3’,5’),111.2(C-9”’),103.2(C-10),95.6(C-6),94.6(C-8),79.0(C-2),66.4(C-1”),55.4(2×-OCH3),54.8(C-3”),53.2(C-5”’,9”’),49.8(C-2”’,6”’),43.2(C-3),29.7(C-2”).
实施例5:5-羟基-2-(4-甲氧基苯基)-7-(4-(4-(6-氟-苯并[d]异噁唑-3-基)哌啶-1-基)丁氧基)苯并二氢吡喃-4-酮(P5)的合成
操作同实施例1,在步骤7)中使用6-氟-3-(4-哌啶基)-1,2-苯异噁唑作为反应物,所得产物P5为黄色油状物。
ESI+-MS:560.8[M+H]+
HR-Q-TOF-MS:561.2447[M+H]+(calcd for C32H33FN2O6,561.2395).
1H NMR(300MHz,CDCl3):δ=12.05(br s,1H,OH-5),7.40(dd,1H,J=8.7,5.1Hz,Ar-H),7.44(d,2H,J=8.7Hz,Ar-H),7.25(dd,2H,J=8.7,2.1Hz,Ar-H),7.07(dt,1H,J=9.0,2.1Hz,Ar-H),6.97(d,2H,J=8.7Hz,Ar-H),6.08(d,1H,J=2.1Hz,H-8),6.06(br s,1H,J=2.4Hz,H-6),5.40(dd,1H,J=13.2,3.0Hz,H-2),4.03(t,2H,J=6.0Hz,H-1”),3.85(s,3H,-OCH3),3.12(m,4H,H2-4”;H-8”;H-3α),2.81(dd,1H,J=17.1,3.0Hz,H-3β),2.47(t,2H,J=7.2Hz,H-6”),2.08(m,6H,H2-7”;H2-9”;H2-10”),1.83(m,2H,H-2”),1.70(m,2H,H-3”).13C NMR(300MHz,CDCl3):δ=195.9(C-4),167.5(C-7),164.1(C-6”’),162.9(C-5),161.1(C-9),160.1(C-4’),130.5(C-1’),127.7(C-2’,6’),122.7(C-8”’),122.5(C-6”’),117.3(C-3”’),114.4(C-3’,5’),112.5(C-9”’),112.1(C-9”’),103.1(C-10),97.6(C-7”’),97.2(C-7”’),95.5(C-6),94.6(C-8),79.0(C-2),68.3(C-1”),58.3(C-4”),55.4(-OCH3),53.5(C-6”,10”),43.2(C-3),34.6(C-8”),30.5(C-7”,9”),27.0(C-2”),23.3(C-3”).
实施例6:5-羟基-2-(4-氟基苯基)-7-(4-(4-(6-氟-苯并[d]异噁唑-3-基)哌啶-1-基)丁氧基)苯并二氢吡喃-4-酮(P4)的合成
操作同实施例1,在步骤3)中使用对氟苯甲醛作为反应物;在步骤7)中使用6-氟-3-(4-哌啶基)-1,2-苯异噁唑作为反应物,所得产物为黄色油状物。
ESI+-MS:548.8[M+H]+
HR-Q-TOF-MS:549.2273[M+H]+(calcd for C31H30F2N2O5,549.2196).
1H NMR(300MHz,CDCl3):δ=12.04(br s,1H,OH-5),7.40(dd,2H,J=8.7,5.1Hz,Ar-H),7.44(m,2H,Ar-H),7.24(dd,2H,J=8.7,2.1Hz,Ar-H),7.09(m,4H,Ar-H),6.08(d,1H,J=2.1Hz,H-8),6.05(br s,1H,J=2.4Hz,H-6),5.40(dd,1H,J=12.6,3.0Hz,H-2),4.03(t,2H,J=6.0Hz,H-1”),3.06(m,4H,H2-4”;H-8”;H-3α),2.80(dd,1H,J=17.1,3.0Hz,H-3β),2.48(t,2H,J=7.2Hz,H-6”),2.05(m,6H,H2-7”;H2-9”;H2-10”),1.83(m,2H,H-2”),1.70(m,2H,H-3”).13C NMR(300MHz,CDCl3):δ=195.9(C-4),167.5(C-7),164.1(C-4”’),162.6(C-5),161.0(C-9),134.3(C-4’),134.3(C-1’),128.0(C-2’,6’),122.7(C-8”’),122.5(C-6”’),117.3(C-9”’),115.9(C-3’),115.7(C-3’),112.5(C-1”’),112.1(C-7”’),103.0(C-10),97.2(C-5”’),95.7(C-6),94.6(C-8),78.5(C-2),68.3(C-1”),58.2(C-4”),53.4(C-6”,10”),30.4(C-7”,9”),43.3(C-3),34.5(C-8”),26.9(C-2”),23.2(C-3”).
实施例7:5-羟基-2-(4-甲氧基苯基)-7-(4-(4-(6-氟-苯并[d]异噁唑-3-基)哌啶-1-基)丙氧基)苯并二氢吡喃-4-酮(P7)的合成
操作同实施例1,在步骤6)中使用1,3-二溴丙烷作为反应物;在步骤7)中使用6-氟-3-(4-哌啶基)-1,2-苯异噁唑作为反应物,所得产物为黄色油状物。
ESI+-MS:546.9[M+H]+
HR-Q-TOF-MS:547.2309[M+H]+(calcd for C31H31FN2O6,547.2239).
1H NMR(300MHz,CDCl3):δ=12.04(br s,1H,OH-5),7.72(dd,1H,J=8.4,5.1Hz,Ar-H),7.39(d,2H,J=8.4Hz,Ar-H),7.25(m,1H,Ar-H),7.06(dt,1H,J=9.0,2.1Hz,Ar-H),6.96(d,2H,J=8.4Hz,Ar-H),6.10(br s,1H,H-8),6.08(br s,1H,H-6),5.40(dd,1H,J=12.9,2.1Hz,H-2),4.08(t,2H,J=6.0Hz,H-1”),3.84(s,3H,-OCH3),3.11(m,4H,H2-3”;H-8”;H-3α),2.81(dd,1H,J=17.1,2.7Hz,H-3β),2.60(t,2H,J=7.2Hz,H-5”),2.09(m,8H,H2-2”;H2-6”;H2-8”;H2-9”).13C NMR(300MHz,CDCl3):δ=196.0(C-4),167.4(C-7),164.1(C-6”’),162.9(C-5),161.0(C-9),160.0(C-4’),130.4(C-1’),127.7(C-2’,6’),122.7(C-8”’),122.6(C-6”’),117.3(C-3”’),114.2(C-3’,5’),112.5(C-9”’),112.2(C-9”’),103.1(C-10),97.6(C-7”’),95.6(C-6),94.6(C-8),79.0(C-2),66.7(C-1”),55.4(-OCH3),55.0(C-3”),53.5(C-5”,9”),43.2(C-3),34.5(C-7”),30.4(C-6”,8”),30.0(C-2”),26.5(C-3”).
B.本发明化合物的药理研究
实验例1:本发明化合物对LPS+INF-γ致小胶质细胞炎症反应的影响
实验目的:小胶质细胞活化和神经炎症是中枢神经系统许多疾病的重要发病机制。致炎物质细菌内毒素脂多糖(lipopolysaccharides,LPS)以及干扰素γ(interferon-γ,IFN-γ)可刺激机体产生前炎症细胞因子,后者触发瀑布式炎症级联反应,进一步激活小胶质细胞等炎症细胞,释放炎性介质一氧化氮(nitric oxide,NO)等,形成炎症网络。本实验通过建立LPS+INF-γ联合致小胶质细胞(BV2细胞)炎症模型,研究本发明合成的新型化合物对小胶质细胞炎症的抑制作用。
实验方法:取处于对数生长期的BV2细胞(小鼠小胶质细胞系)接种于96孔培养板,置37℃、5%CO2培养箱中培养。24h后,加入不同浓度的化合物,培养24h后弃培养液,加入LPS+INF-γ作用24h,收集上清液。以NO的稳定性代谢产物亚销酸盐作为检测NO的指标,用Griess试剂盒测定。
实验结果:如图1所示,LPS+INF-γ诱导BV2细胞(小胶质细胞)产生和释放炎性介质NO明显增多。本发明化合物都具有抑制LPS+INF-γ致BV2细胞NO过度生成和释放的作用,表明这些化合物具有明显的拮抗神经炎症的作用。
结果提示本发明化合物可用于防治精神分裂症、抑郁症等精神障碍,以及神经退行性疾病(如阿尔茨海默病、帕金森病)、脑血管病、脑创伤、脊髓损伤、脱髓鞘病、多发性硬化、炎症性脱髓鞘性多发性神经病等神经系统疾病。
实验例2:本发明化合物对多巴胺2型受体活性的影响
实验目的:精神分裂症患者的阳性症状(幻觉、妄想等)可能与皮质下边缘系统多巴胺(DA)功能亢进有关,阻断多巴胺2型受体(DRD2)的抗精神病药物能有效控制精神分裂症的阳性症状。通过建立共转DRD2和Gα16的细胞系,使得DRD2被激活后能引起Gα16蛋白的活化,进而激活磷脂酶C(PLC)产生IP3和DAG,IP3可与细胞内质网和线粒体上的IP3受体结合,从而引起胞内钙的释放。因此,测定胞内钙的变化可以作为检测DRD2活化状态的方法。Fluo-4/AM是一种钙荧光探针指示剂用来测量钙离子。本实验应用Fluo-4荧光法,通过测量被细胞内钙离子激发的荧光强度来反映Gα蛋白被激活的水平。如果化合物能够激动DRD2,则可以使钙流反应升高;反之,如果化合物能够拮抗DRD2,则使钙流反应降低。
实验方法:将稳定表达DRD2/Gα16的HEK293细胞种于96孔板,培养过夜。吸去培养液,加入新鲜配制的染料Fluo-4/AM,37℃培养箱内孵育40分钟。将染料吸尽弃去,用新鲜配制的钙缓冲液洗一遍后,换上50μl溶解有待测药物的钙缓冲液。用FlexStation II仪检测,第15秒开始由仪器自动加入25μl溶解有已知激动剂的钙缓冲液,最终读取525nm处荧光值(激发波长设为485nm)。以多巴胺(Dopamine)为激动剂,Eticlopride(依替必利,D2受体拮抗剂)为拮抗剂,通过以下公式计算得到各样品各浓度条件下的细胞反应率(%Response):%Response=(LSample-LBlank)/(LDopamine-LBlank)。LSample表示待测样品的检测信号值,LBlank表示Eticlopride完全抑制的检测信号值,LDopamine表示50nM激动剂Dopamine刺激DMSO组后的检测信号值。IC50值是通过GraphPad Prism计算得到。
实验结果:从表1和图2看出,本发明化合物P1~P7都具有抑制多巴胺2型受体(DRD2)的活性,并具有一定量效关系。结果提示本发明化合物可用于防治精神分裂症等精神障碍。
表1.本发明部分化合物抑制多巴胺2型受体的IC50值
实验例3:本发明化合物对NMDA受体拮抗剂致精神分裂症小鼠模型的影响
实验目的:谷氨酸传递低下是精神分裂症等精神障碍的发病机制之一,N-甲基-D-天冬氨酸(N-methyl-D-aspartic acid,NMDA)受体拮抗剂能够诱导精神分裂症样效应。本实验采用NMDA受体拮抗剂地卓西平(MK-801)诱导小鼠的高活动性精神分裂症模型,对本发明化合物P6、P5、P4、P7进行体内活性评价。
实验方法:选择无特殊病原体SPF级近交系Balb/c雄性小鼠,体重(20±2)g,随机分为正常对照组、模型组、本发明药物组。小鼠先适应饲养环境1周,连续灌胃给药3天,第四天在测试前给药,随后放入旷场行为红外监视系统仪器中开始测试60分钟,然后对照组腹腔注射生理盐水,模型组、给药组腹腔注射NMDA受体拮抗剂地卓西平(MK-801)溶液0.6mg/kg,继续测定各组小鼠210分钟内的自发活动性和中央区活动情况。其中,自发活动用来反映精神分裂症中快速移动的阳性症状;中央区活动情况用来评价精神分裂症的焦虑状态。
实验结果:应用旷场试验检测小鼠自主活动情况,结果显示:与对照组相比,MK-801模型组小鼠210分钟内的自发活动总路程和中央区活动距离延长;本发明化合物P6、P5、P7灌胃给药能够缩短MK-801模型小鼠的自发活动总路程和中央区活动距离(图3,图4,图5,表2)。结果提示本发明化合物可减轻精神分裂症的阳性症状和焦虑状态。
表2.本发明化合物对MK-801致精神分裂症高活动模型小鼠210分钟内自发活动总路程及中央区活动距离的影响(旷场试验)
数据以Mean±SE表示,每组n=10;##P<0.01,模型组与对照组相比;*P<0.05,给药组与模型组相比。
实验例4:本发明化合物对Cuprizone小鼠模型行为学变化的影响
实验目的:神经炎症、白质病变、髓鞘脱失是中枢神经系统许多疾病和精神障碍的重要发病机制。Cuprizone(双环己酮草酰二腙)可引起炎症反应、髓鞘脱失、轴突损伤、认知功能损害等变化。本实验应用Y-迷宫和旷场行为试验研究了本发明化合物对Cuprizone小鼠模型记忆功能和运动情况的影响。
实验方法:选择SPF级近交系C57BL/6雄性小鼠,体重(20±2)g,随机分为正常对照组、模型组、本发明药物组。小鼠先适应饲养环境3天,然后除了对照组给予正常饲料以外,其它各组均给予含0.2%Cuprizone的饲料进行造模,造模的同时各组灌胃相应剂量的药物,连续饲养5周,然后进行Y-迷宫和旷场行为测试。其中,Y-迷宫的进臂次数用来反映小鼠的运动情况;Y-迷宫的自发性交替反应(Alternation)用来反映小鼠的工作记忆情况;旷场行为的自发活动性用来反映小鼠的运动情况。
实验结果:Y-迷宫试验的结果显示,与对照组相比,Cuprizone模型小鼠的进臂次数增高,自发性交替反应减低;本发明化合物P6、P5灌胃给药能够减低模型小鼠的进臂次数(图6),增高自发性交替反应(图7)。旷场行为试验的结果显示,与对照组相比,Cuprizone模型小鼠的自发活动总路程延长;本发明化合物P6、P5灌胃给药能够缩短模型小鼠的自发活动总路程(图8)。结果表明本发明化合物能够改善Cuprizone模型小鼠的认知功能和运动行为,减低模型小鼠的高活动状态。
实验例5:本发明化合物对Cuprizone小鼠模型髓鞘脱失的影响
实验目的:神经白质病变、髓鞘脱失是中枢神经系统许多疾病和精神障碍的重要发病机制。Cuprizone可引起髓鞘脱失和神经白质病变。髓鞘碱性蛋白(MBP)是轴突髓鞘化的标志性蛋白,是髓鞘的主要组成成分。本实验应用蛋白免疫印迹(western blot)方法研究本发明化合物对Cuprizone模型小鼠脑内MBP含量及髓鞘脱失的影响。
实验方法:Cuprizone小鼠造模与给药方法同实验例11。小鼠进行行为学检测后,腹腔注射10%水合氯醛进行麻醉,取脑,于-80℃保存。Western blot检测:取脑组织用裂解液提取蛋白,测蛋白浓度。进行SDS-PAGE凝胶电泳,转膜,封闭。于4℃冰箱与抗MBP抗体(一抗)孵育过夜。在TBST漂洗后,于4℃冰箱与二抗孵育2h。TBST洗膜后,在暗室中加入ECL发光液,压片,曝光。各蛋白条带的信号强度用FluorChem 8900灰度分析软件进行分析。
实验结果:应用western blot方法检测,结果显示:与正常对照组相比,Cuprizone模型组小鼠额叶皮层髓鞘碱性蛋白(MBP)含量明显降低;本发明化合物P5、P4能够显著升高模型小鼠的MBP含量,表明具有改善髓鞘脱失的作用(图9)。
结果提示本发明化合物可用于防治精神分裂症、抑郁症和其他精神障碍,以及脑血管病、脱髓鞘病、多发性硬化、炎症性脱髓鞘性多发性神经病、缺血-缺氧性病引起的白质脑病、糖尿病性神经病等疾病。
实验例6:本发明化合物对Cuprizone小鼠模型小胶质细胞活化的影响
实验目的:小胶质细胞活化和神经炎症是中枢神经系统许多疾病的重要发病机制。Iba-1能够特异标志小胶质细胞。本实验应用免疫组织化学方法研究本发明化合物对Cuprizone小鼠模型脑内Iba-1标志的小胶质细胞的影响。
实验方法:Cuprizone小鼠造模与给药方法同实验例11。小鼠进行行为学检测后,腹腔注射10%水合氯醛进行麻醉。灌注后,取出脑组织,用15%多聚甲醛固定脑组织,然后进行冰冻切片。免疫组织化学染色:冰冻切片用3%的H2O2灭活10min,PBS漂洗;10%的血清封闭,37℃孵育1h。洗出血清,滴加一抗(抗Iba-1抗体),4℃过夜。用PBST漂洗,滴加生物素标记的二抗,37℃孵育2h。用PBST漂洗,滴加辣根酶标记的链酶卵白素三抗,37℃孵育2h。用PBS漂洗,DAB试剂显色,透明,封片。在显微镜下观察Iba-1阳性细胞,计数。
实验结果:免疫组织化学染色结果显示,与正常对照组相比,Cuprizone模型组脑内Iba-1标记的小胶质细胞数量明显增多,表明小胶质细胞活化,出现炎症反应;本发明化合物P6(25、50mg/kg)能够明显减少小胶质细胞数量,表明能够抑制小胶质细胞活化,减轻炎性反应(图10)。
结果提示本发明化合物可用于防治精神分裂症、抑郁症等精神障碍,以及神经退行性疾病(如阿尔茨海默病、帕金森病)、脑血管病、脑创伤、脊髓损伤、脱髓鞘病、多发性硬化、炎症性脱髓鞘性多发性神经病等神经系统疾病。
综上所述,本发明提供了一类式I所示的结构新颖的化合物,这些化合物能够拮抗多巴胺2型受体,抑制小胶质细胞激活和神经炎症反应;动物实验结果表明,本发明化合物可降低MK-801小鼠模型的高活动性,并能缓解其焦虑状态;能够改善Cuprizone模型小鼠的记忆功能障碍、异常运动行为和高活动性,并能抑制模型小鼠的小胶质细胞活化和髓鞘脱失。这些结果表明本发明化合物具有防治多种精神障碍和神经系统疾病的用途。
尽管本发明的具体实施方式已经得到详细的描述,本领域技术人员将会理解,根据已经公开的所有教导,对本发明细节进行的各种修改和替换均在本发明的保护范围之内。本发明的全部范围由所附权利要求及其任何等同物给出。
Claims (13)
1.式(I)所示化合物或其药学上可接受的盐,
其中:
R1、R2、R3、R4、R5、R6、R7和R8各自独立地选自氢、卤素、氰基、羟基、氨基、C1-6烷基(例如甲基)、C1-6烷氧基(例如甲氧基)、C1-6烷氨基和芳基,任选地,其中所述C1-6烷基、C1-6烷氧基、C1-6烷氨基和芳基各自独立地被一个或多个选自卤素、氨基和羟基的取代基取代,优选地,其中所述卤素为氯或氟;
X为含有2-6个碳原子的饱和或部分饱和的亚链烃基,任选地,其中所述亚链烃基被选自羟基或甲基的取代基取代;
Y为-N-或-C(R)-,其中所述R基选自氢、羟基、氨基、C1-6烷基;
Z为芳基或杂芳基。
2.权利要求1的化合物或其药学上可接受的盐,其中,R3和R8各自独立地选自氢、卤素(例如氟或氯)、C1-6烷基(例如甲基)和C1-6烷氧基(例如甲氧基),任选地,其中所述C1-6烷基和C1-6烷氧基各自独立地被一个或多个选自卤素、氨基和羟基的取代基取代。
3.权利要求1或2的化合物或其药学上可接受的盐,其中,R1、R2、R4、R5、R6和R7均为氢。
4.权利要求1-3任一项的化合物或其药学上可接受的盐,其中,Y为-N-或-C(R)-,R选自氢、羟基或甲基。
5.权利要求1-4任一项的化合物或其药学上可接受的盐,其中,X为C2-6亚烷基(例如C2-4亚烷基,再例如1,2-亚乙基、1,3-亚丙基或1,4-亚丁基),任选地,所述C2-6亚烷基被选自羟基或甲基的取代基取代。
6.权利要求1-5任一项的化合物或其药学上可接受的盐,其中Z为含5-20个碳原子(例如5-15个碳原子,再例如5-10个碳原子)的芳基或杂芳基,优选地,所述芳基或杂芳基选自苯基、萘基、吡咯基、呋喃基、噻吩基、咪唑基、吡唑基、噁唑基、异噁唑基、噻唑基、异噻唑基、三氮唑基、吡啶基、吡喃基、嘧啶基、吡嗪基、哒嗪基、三嗪基、吲哚基、苯并呋喃基、苯并噻吩基、苯并咪唑基、苯并吡唑基、苯并噁唑基、苯并异噁唑基、苯并噻唑基、苯并异噻唑基、苯并三氮唑基、喹啉基、苯并吡喃基、苯并嘧啶基、喹喔啉基、苯并哒嗪基、苯并三嗪基和嘌呤基。
7.权利要求1的化合物或其药学上可接受的盐,其中所述化合物选自:
5-羟基-2-(4-甲氧基苯基)-7-(4-(4-(2-甲氧基苯基)哌嗪-1-基)丁氧基)苯并二氢吡喃-4-酮;
5-羟基-2-(4-甲基苯基)-7-(4-(4-(2-甲氧基苯一基)哌嗪-1-基)丁氧基)苯并二氢吡喃-4-酮;
5-羟基-2-(4-氟基苯基)-7-(4-(4-(2-甲氧基苯基)哌嗪-1-基)丁氧基)苯并二氢吡喃-4-酮;
5-羟基-2-(4-甲氧基苯基)-7-(4-(4-(2-甲氧基苯基)哌嗪-1-基)丙氧基)苯并二氢吡喃-4-酮;
5-羟基-2-(4-甲氧基苯基)-7-(4-(4-(6-氟-苯并[d]异噁唑-3-基)哌啶-1-基)丁氧基)苯并二氢吡喃-4-酮;
5-羟基-2-(4-甲氧基苯基)-7-(4-(4-(6-氟-苯并[d]异噁唑-3-基)哌啶-1-基)丙氧基)苯并二氢吡喃-4-酮;和
5-羟基-2-(4-氟基苯基)-7-(4-(4-(6-氟-苯并[d]异噁唑-3-基)哌啶-1-基)丁氧基)苯并二氢吡喃-4-酮。
8.药物组合物,其包含权利要求1-7任一项的化合物或其药学上可接受的盐,以及任选地一种或几种药学上可接受的辅料(如载体和/或赋形剂)。
9.权利要求1-7任一项所述的化合物或其药学上可接受的盐的制备方法,其包括以下步骤:
1)化合物A与乙酰氯经酰基化反应得到化合物B;
2)在化合物B的羟基上引入保护基得化合物C;
3)化合物C与化合物D发生羟醛缩合反应制得化合物E;
4)化合物E经关环反应得化合物F;
5)化合物F脱羟基保护基得化合物G;
6)化合物G与化合物H经亲核取代得到化合物I;
7)化合物I与化合物J经亲核取代得到式I化合物;
其中,PG代表羟基保护基,例如MOM、TMS或TBS等;L表示亲核取代反应的离去基团,例如卤素、-OTs、-OCOR(R代表烷基)等;
其余各原子或取代基定义如权利要求1所述。
10.权利要求1-7任一项所述的化合物或其药学上可接受的盐或者权利要求7的药物组合物在制备用于预防或治疗精神障碍或神经系统疾病的药物中的用途。
11.权利要求10的用途,其中所述精神障碍选自精神分裂症、抑郁症、躁狂抑郁性精神障碍(双相障碍)、认知障碍、焦虑症、应激相关障碍、注意缺陷与多动障碍、抽动障碍,以及各种器质性病变伴发的精神障碍。
12.按照权利要求11的用途,其中所述各种器质性病变伴发的精神障碍选自阿尔茨海默病、血管性痴呆、脑外伤所致精神障碍、颅内感染所致精神障碍、脑肿瘤所致精神障碍、梅毒所致精神障碍、癫痫性精神障碍、HIV/AIDS所致精神障碍。
13.权利要求10的用途,其中所述神经系统疾病选自神经退行性疾病(例如阿尔茨海默病或帕金森病)、脑血管病、脑创伤、脊髓损伤、脱髓鞘病、多发性硬化、炎症性脱髓鞘性多发性神经病、缺血-缺氧性病引起的白质脑病和糖尿病性神经病。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610032327.6A CN106977506B (zh) | 2016-01-19 | 2016-01-19 | 二氢黄酮衍生物、其制备方法和用途 |
PCT/CN2017/070877 WO2017124949A1 (zh) | 2016-01-19 | 2017-01-11 | 二氢黄酮衍生物、其制备方法和用途 |
US16/071,472 US10513512B2 (en) | 2016-01-19 | 2017-01-11 | Flavanone derivatives, and preparation method and use thereof |
EP17740980.2A EP3406611B9 (en) | 2016-01-19 | 2017-01-11 | 5-hydroxy-2-(4-methoxyphenyl)-7-(butoxy)-chroman-4-one derivatives acting on dopaminergic and glutamatergic systems, microglial cells and brain white matter, for treating mental disorders or nervous system diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610032327.6A CN106977506B (zh) | 2016-01-19 | 2016-01-19 | 二氢黄酮衍生物、其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106977506A true CN106977506A (zh) | 2017-07-25 |
CN106977506B CN106977506B (zh) | 2020-04-24 |
Family
ID=59340337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610032327.6A Active CN106977506B (zh) | 2016-01-19 | 2016-01-19 | 二氢黄酮衍生物、其制备方法和用途 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10513512B2 (zh) |
EP (1) | EP3406611B9 (zh) |
CN (1) | CN106977506B (zh) |
WO (1) | WO2017124949A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109761945A (zh) * | 2019-01-31 | 2019-05-17 | 南阳师范学院 | 一种柚皮素-o-烷基胺类化合物、制备方法和应用 |
CN115160279A (zh) * | 2022-07-27 | 2022-10-11 | 中国药科大学 | 苯并吡喃酮类化合物、药物组合物和应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11905799B2 (en) | 2021-07-18 | 2024-02-20 | Cnpc Usa Corporation | Hybrid battery pack system |
CN116063264A (zh) * | 2023-04-06 | 2023-05-05 | 北京大学第一医院 | 一种改善内皮功能障碍的化合物的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103450174A (zh) * | 2013-09-07 | 2013-12-18 | 吉首大学 | 苯并吡喃酮-苯基-噁唑烷酮型化合物及其制法和用途 |
CN104059046A (zh) * | 2013-03-18 | 2014-09-24 | 江苏恩华药业股份有限公司 | 黄酮类衍生物及其应用 |
CN103435601B (zh) * | 2013-09-07 | 2015-10-28 | 吉首大学 | 一类多靶点黄酮-喹啉酮型化合物及其制法和用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8008344B2 (en) | 2007-09-14 | 2011-08-30 | NatureWise Biotech and Medicals Corporation | Compounds for the inhibition of histone deacetylase |
CN103694233B (zh) | 2013-12-10 | 2016-08-17 | 沈阳药科大学 | 苯并异噁唑类化合物及其应用 |
-
2016
- 2016-01-19 CN CN201610032327.6A patent/CN106977506B/zh active Active
-
2017
- 2017-01-11 EP EP17740980.2A patent/EP3406611B9/en active Active
- 2017-01-11 US US16/071,472 patent/US10513512B2/en active Active
- 2017-01-11 WO PCT/CN2017/070877 patent/WO2017124949A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104059046A (zh) * | 2013-03-18 | 2014-09-24 | 江苏恩华药业股份有限公司 | 黄酮类衍生物及其应用 |
CN103450174A (zh) * | 2013-09-07 | 2013-12-18 | 吉首大学 | 苯并吡喃酮-苯基-噁唑烷酮型化合物及其制法和用途 |
CN103435601B (zh) * | 2013-09-07 | 2015-10-28 | 吉首大学 | 一类多靶点黄酮-喹啉酮型化合物及其制法和用途 |
Non-Patent Citations (3)
Title |
---|
ZHU-PING XIAO ET AL.: "Design,synthesis,and evaluation of novel fluoroquinolone-flavonoid hybrids as potent antibiotics against drug-resistant microorganisms", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
张楫: "天然黄酮类化合物的合成研究", 《中国优秀硕士学位论文全文数据库》 * |
陈寅: "新型多靶点抗精神分裂药物的设计、合成及生物活性评价", 《中国博士学位论文全文数据库》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109761945A (zh) * | 2019-01-31 | 2019-05-17 | 南阳师范学院 | 一种柚皮素-o-烷基胺类化合物、制备方法和应用 |
CN115160279A (zh) * | 2022-07-27 | 2022-10-11 | 中国药科大学 | 苯并吡喃酮类化合物、药物组合物和应用 |
CN115160279B (zh) * | 2022-07-27 | 2023-11-24 | 中国药科大学 | 苯并吡喃酮类化合物、药物组合物和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106977506B (zh) | 2020-04-24 |
US10513512B2 (en) | 2019-12-24 |
US20190031644A1 (en) | 2019-01-31 |
EP3406611B9 (en) | 2021-10-13 |
WO2017124949A1 (zh) | 2017-07-27 |
EP3406611B1 (en) | 2021-05-19 |
EP3406611A1 (en) | 2018-11-28 |
EP3406611A4 (en) | 2019-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101987849B (zh) | 治疗与年龄相关的黄斑变性(amd)的方法 | |
US8486990B2 (en) | SirT inhibitors that bind to NAD | |
US20010020028A1 (en) | Agents for treating neurodegenerative disorders | |
US20050250794A1 (en) | Methods of treating a disorder | |
CN107286077A (zh) | 一种选择性的c-kit激酶抑制剂 | |
CN106580987B (zh) | 二氢巴马汀抗溃疡性结肠炎的用途 | |
CN106977506A (zh) | 二氢黄酮衍生物、其制备方法和用途 | |
CN107613771A (zh) | 化合物及其作为β‑分泌酶1抑制剂的用途 | |
EP2985283B1 (en) | Anti-angiogenesis compound, intermediate and use thereof | |
UA120353C2 (uk) | Модулятори натрієвого каналу для лікування болю і діабету | |
CN102803269A (zh) | Ampk的噻吩并[2,3-b]嘧啶二酮活化剂及其治疗用途 | |
CN112654616A (zh) | 3-芳氧基-3-芳香基-丙胺类化合物及其用途 | |
TW213917B (zh) | ||
US8653069B2 (en) | Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia | |
US20050209300A1 (en) | Methods of treating a disorder | |
JP2021113819A (ja) | 皮膚におけるc−Jun N末端キナーゼの阻害の測定方法 | |
CN105873921A (zh) | 苯并咪唑-脯氨酸衍生物的用途 | |
CN108653276A (zh) | 一种3-芳基香豆素类化合物的应用 | |
CH674203A5 (zh) | ||
AU2018297856A1 (en) | Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases | |
CN110507646A (zh) | 青蒿素衍生物在制备抗焦虑症的药物或缓解焦虑症的食品中的应用 | |
US20080214800A1 (en) | Sirt inhibitors that bind to nad | |
EP3409664A1 (en) | Application of substituted cinnamamide derivatives in preparation of anti-anxiety medications | |
KR101686872B1 (ko) | Tlr4에 lps와의 경쟁적 결합을 통한 항산화 및 항염증 활성을 갖는 신규 화합물 및 이의 의학적 용도 | |
CN100480253C (zh) | 含烷胺基烷氧基取代的糖碳甙异黄酮化合物及其制法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |